scholarly journals Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney Disease

2020 ◽  
Vol 23 ◽  
pp. 278-288
Author(s):  
Hongzhen Zhong ◽  
Wenshan Lin ◽  
Tianbiao Zhou
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hypoxia Inducible Factor ◽  
Phosphorus Metabolism ◽  
Common Complication ◽  
Public Attention ◽  
Common Causes ◽  
Incident Heart Failure ◽  
Calcium And Phosphorus ◽  
Erythropoietin Stimulating Agents

Anemia is a common complication of chronic kidney disease (CKD), and its prevalence has shown a tendency to increase in many countries. Anemia is associated with incident heart failure and increases mortality in CKD patients, garnering public attention. Here, we reviewed recent studies about CKD with anemia, and tried to summarize the risks and causes and new progress in the treatment of renal anemia. Among the risks and causes, calcium and phosphorus metabolism disorders should be pointed out along with common causes such as iron and erythropoietin deficiencies, hypoxia, inflammation and uremic toxins, and so on. The new anti-anemia treatments mainly include hematopoietic materials supplementation, erythropoietin-stimulating agents, calcium and phosphorus regulators and hypoxia-inducible factor prolyl hydroxylase inhibitors.

scholarly journals Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease

2012 ◽  
Vol 15 (4) ◽  
pp. 74-80 ◽  
Author(s):  
Margarita Stanislavovna Biragova ◽  
Svetlana Alexandrovna Gracheva ◽  
Sergey Andreevich Martynov
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mineral Metabolism ◽  
Hormone Secretion ◽  
Therapeutic Agents ◽  
Phosphorus Metabolism ◽  
Novel Approach ◽  
Patients With Diabetes ◽  
Per Se ◽  
Calcium And Phosphorus

Disturbance of bone and mineral metabolism (BMM) is one of manifestations of chronic kidney disease (CKD), but its significance goes beyond bone disorders per se. Current discourse is as broad as to include vascular calcification, anemia and arterial hypertension, - conditions increasing mortality in patients with CKD. In this regard the active search for and development of novel approach to correction of BMM is under way. Apart from capacity to normalize calcium and phosphorus metabolism, parathyroid hormone secretion and to reduce morphologic alterations of bone tissue, modern therapeutic agents feature cardio- and renoprotective capabilities, which make them a treatment of choice for compromised BMM in CKD.

scholarly journals Research of the level of erythropoietin and hypoxia-inducible factor 1-alpha in the blood of children and adolescents with anemia at stage C1–5 of chronic kidney disease

2020 ◽  
Vol 65 (1) ◽  
pp. 77-85
Author(s):  
E. V. Leonteva ◽  
N. D. Savenkova
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Therapy Group ◽  
Hypoxia Inducible Factor ◽  
Hypoxia Inducible Factor 1 ◽  
Group 3 ◽  
Group 2 ◽  
Erythropoietin Stimulating Agents ◽  
Group 1

Purpose. To examine the indicators of iron deficiency, the levels of hemoglobin, erythropoietin, hypoxia-induced factor 1-alpha (HIF-1α) in the blood of children with anemia and chronic kidney disease C1-5 prior to the dialysis and on its background, receiving and not receiving iron preparations and erythropoietin-stimulating drugs to establish the role of HIF-1α in the regulation of erythropoietin synthesis and erythropoiesis. Results. The patients (n=80) with anemia and chronic kidney disease were divided into 3 groups: Group 1: 32 patients with chronic kidney disease C1-5 prior to the dialysis, not receiving therapy; Group 2: 18 patients with chronic kidney disease C2-5 prior to the dialysis, receiving iron-containing preparations and erythropoietin-stimulating drugs; Group 3: 30 patients with chronic kidney disease C3-5 on dialysis, receiving iron preparations and erythropoietin-stimulating drugs. Group 1: we found the increased levels of erythropoietin (28.65 ± 3.66 MIU/ml) and HIF-1α (0.089 ± 0.011 ng/ml; p=0.014 and p=0.005, respectively); Group 2: 63.01 ± 14.84 mIU/ml and 0.138 ± 0.025 ng/ml; p=0.0088 and p=0.005, respectively). Group 3: we found the increased level of HIF-1α (0.098 ± 0.01 ng/ml; p=0.005).Conclusion. An increase in concentration of HIF-1α in children with anemia and chronic kidney disease C1-5 prior and on dialysis receiving and not receiving therapy with iron-containing drugs and erythropoietin-stimulating agents confirms the role of HIF-1α in the regulation of erythropoietin and erythropoiesis synthesis in anemia. 

Inferring Disease Mechanisms from Epidemiological Data in Chronic Kidney Disease: Calcium and Phosphorus Metabolism

2009 ◽  
Vol 112 (3) ◽  
pp. c137-c147 ◽  
Author(s):  
Ana Pires ◽  
Teresa Adragão ◽  
Maria João Pais ◽  
José Vinhas ◽  
Hugo Gil Ferreira
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Epidemiological Data ◽  
Phosphorus Metabolism ◽  
Disease Mechanisms ◽  
Calcium And Phosphorus

Calcium and Phosphorus Homeostasis in Dogs with Spontaneous Chronic Kidney Disease at Different Stages of Severity

2010 ◽  
Vol 24 (1) ◽  
pp. 73-79 ◽  
Author(s):  
O. Cortadellas ◽  
M.J. Fernández del Palacio ◽  
J. Talavera ◽  
A. Bayón
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Calcium And Phosphorus

Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis

2021 ◽  
pp. 1-4
Author(s):  
Sijia Li ◽  
Xueqin Chen ◽  
Penghua Hu ◽  
Suijing Wu ◽  
Jianchao Ma ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Immunosuppressive Therapy ◽  
Recombinant Human Erythropoietin ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Common Complication ◽  
Normal Range ◽  
Red Cell Aplasia ◽  
Human Erythropoietin

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

Sign in / Sign up

Export Citation Format

Share Document